Due to the toxicity of petroleum compounds, the increasing accidents of marine oil spills/leakages have had a significant impact on our environment. Recently, different remedial techniques for the treatment of marine petroleum pollution have been proposed, such as bioremediation, controlled burning, skimming, and solidifying. (Hedlund and Staley in Int J Syst Evol Microbiol 51: [61][62][63][64][65][66] 2001). This review introduces an important remedial method for marine oil pollution treatment-bioremediation technique-which is considered as a reliable, efficient, cost-effective, and eco-friendly method. First, the necessity of bioremediation for marine oil pollution was discussed. Second, this paper discussed the species of oil-degrading microorganisms, degradation pathways and mechanisms, the degradation rate and reaction model, and the factors affecting the degradation. Last, several suggestions for the further research in the field of marine oil spill bioremediation were proposed.

No abstract

Chlorinated conjugated polymers not only show great potential for the realization of highly efficient polymer solar cells (PSCs) but also have simple and high-yield synthetic routes and low-cost raw materials available for their preparation. However, the study of the structure-property relationship of chlorinated polymers is lagging. Now two chlorinated conjugated polymers, PCl(3)BDB-T and PCl(4)BDB-T are investigated. When the polymers were used to fabricate PSCs with the nonfullerene acceptor (IT-4F), surprisingly, the PCl(3)BDB-T:IT-4F-based device exhibited a negligible power conversion efficiency (PCE) of 0.18 %, while the PCl(4)BDB-T:IT-4F-based device showed an outstanding PCE of 12.33 %. These results provide new insight for the rational design and synthesis of novel chlorinated polymer donors for further improving the photovoltaic efficiencies of PSCs.

Galactosialidosis (GS) is a lysosomal storage disease linked to deficiency of the protective protein/cathepsin A (PPCA). Similarly to GS patients, Ppca-null mice develop a systemic disease of the reticuloendothelial system, affecting most visceral organs and the nervous system. Symptoms include severe nephropathy, visceromegaly, infertility, progressive ataxia, and shortened life span. Here, we have conducted a preclinical, dose-finding study on a large cohort of GS mice injected intravenously at 1 month of age with increasing doses of a GMP-grade rAAV2/8 vector, expressing PPCA under the control of a liver-specific promoter. Treated mice, monitored for 16 weeks post-treatment, had normal physical appearance and behavior without discernable side effects. Despite the restricted expression of the transgene in the liver, immunohistochemical and biochemical analyses of other systemic organs, serum, and urine showed a dose-dependent, widespread correction of the disease phenotype, suggestive of a protein-mediated mechanism of cross-correction. A notable finding was that rAAV-treated GS mice showed high expression of PPCA in the reproductive organs, which resulted in reversal of their infertility. Together these results support the use of this rAAV-PPCA vector as a viable and safe method of gene delivery for the treatment of systemic disease in non-neuropathic GS patients.